Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Down 6.6% – Should You Sell?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) were down 6.6% during trading on Tuesday . The company traded as low as $6.76 and last traded at $6.89. Approximately 183,557 shares changed hands during trading, a decline of 85% from the average daily volume of 1,210,110 shares. The stock had previously closed at $7.38.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They issued a “sell” rating for the company.

Tonix Pharmaceuticals Trading Up 5.7 %

The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The firm has a market cap of $14.58 million, a P/E ratio of 0.00 and a beta of 2.07. The company’s 50 day moving average is $23.27 and its two-hundred day moving average is $21.40.

Institutional Trading of Tonix Pharmaceuticals

Several institutional investors have recently modified their holdings of TNXP. Geode Capital Management LLC lifted its position in Tonix Pharmaceuticals by 1,600.1% in the fourth quarter. Geode Capital Management LLC now owns 1,971,894 shares of the company’s stock worth $650,000 after purchasing an additional 1,855,907 shares during the period. Jane Street Group LLC boosted its position in shares of Tonix Pharmaceuticals by 5,932.3% during the 4th quarter. Jane Street Group LLC now owns 1,662,682 shares of the company’s stock valued at $548,000 after acquiring an additional 1,635,119 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Tonix Pharmaceuticals in the fourth quarter valued at about $526,000. Northern Trust Corp acquired a new position in Tonix Pharmaceuticals in the fourth quarter worth about $162,000. Finally, PFG Investments LLC bought a new position in Tonix Pharmaceuticals during the fourth quarter worth about $72,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.